A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Alfred H.J. Kim; COVID-19 Global Rheumatology Alliance; Bulina Inita

doi:10.7326/M20-1223

A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Alfred H.J. Kim (Corresponding Author), COVID-19 Global Rheumatology Alliance, Bulina Inita (Member of the Working Group)

Research output: Contribution to journal › Comment/debate

165 Citations (Scopus)

18 Downloads (Pure)

Original language	English
Pages (from-to)	819-821
Number of pages	3
Journal	Annals of Internal Medicine
Volume	172
Issue number	12
DOIs	https://doi.org/10.7326/M20-1223
Publication status	Published - 16 Jun 2020
Externally published	Yes

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.7326/M20-1223

A Rush to JudgmentFinal published version, 151 KB

Cite this

@article{aa50707df14d48e990112ec382d511d3,

title = "A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19",

author = "Kim, {Alfred H.J.} and Sparks, {Jeffrey A.} and Liew, {Jean W.} and Putman, {Michael S.} and Francis Berenbaum and Al{\'i} Duarte-Garc{\'i}a and Graef, {Elizabeth R.} and Peter Korsten and Sattui, {Sebastian E.} and Emily Sirotich and Ugarte-Gil, {Manuel F.} and Kate Webb and Rebecca Grainger and {COVID-19 Global Rheumatology Alliance} and Philip Robinson and Jinoos Yazdany and Paul Sufka and Zach Wallace and Suleman Bhana and Jon Hausmann and Pedro Machado and David Liew and Claudia Marques and Diane LaCaille and Sindhu Johnson and Keshini Devakandan and Carter Thorne and Mengtao Li and Johannes Knitza and Richard Conway and Bulina Inita and Tehozol, {Erick Adrian Zamora} and Ibrahim Almaghlouth and Taryn Youngstein and Pedro Machado and Richard Beesley and Kimme Hyrich and Adam Kilian and Maria Danila and Isabelle Amigues and Eugenia Chock and Laura Le-Wandowski and Jon Hausmann and Maximilian Konig and Beth Wallace and Reema Syed and Arundathi Jayatilleke and Namrata Singh and Aarat Patel and Katherine Wysham and Marc Nolan",

note = "Funding Information: Disclosures: Dr. Kim reports personal fees from Exagen Diagnostics and GlaxoSmithKline and grants from the National Institutes of Health and the Rheumatology Research Foundation outside the submitted work. Dr. Sparks reports grants from the National Institute of Allergy and Infectious Diseases Autoimmune Centers of Excellence, National Institutes of Health, during the conduct of the study and personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum outside the submitted work. Dr. Berenbaum reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, No-vartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica, and 4P Pharma outside the submitted work. Dr. Korsten reports personal fees from GlaxoSmith-Kline, Sanofi-Aventis, Pfizer, AbbVie, Novartis Pharma, Lilly, and Bristol-Myers Squibb outside the submitted work. Dr. Sat-tui reports funding from a Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319). Dr. Ugarte-Gil reports grants from Pfizer and Janssen outside the submitted work. Dr. Grainger reports nonfinancial support from Pfizer Australia and Janssen Australia and personal fees from Pfizer Australia, Cornerstones, Janssen New Zealand, and Novartis outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www .acponline.org/authors/icmje/ConflictOfInterestForms.do?ms Num=M20-1223.",

year = "2020",

month = jun,

day = "16",

doi = "10.7326/M20-1223",

language = "English",

volume = "172",

pages = "819--821",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "12",

}

A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. / Kim, Alfred H.J. (Corresponding Author); COVID-19 Global Rheumatology Alliance ; Inita, Bulina (Member of the Working Group).
In: Annals of Internal Medicine, Vol. 172, No. 12, 16.06.2020, p. 819-821.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

AU - Kim, Alfred H.J.

AU - Sparks, Jeffrey A.

AU - Liew, Jean W.

AU - Putman, Michael S.

AU - Berenbaum, Francis

AU - Duarte-García, Alí

AU - Graef, Elizabeth R.

AU - Korsten, Peter

AU - Sattui, Sebastian E.

AU - Sirotich, Emily

AU - Ugarte-Gil, Manuel F.

AU - Webb, Kate

AU - Grainger, Rebecca

AU - COVID-19 Global Rheumatology Alliance

A2 - Robinson, Philip

A2 - Yazdany, Jinoos

A2 - Sufka, Paul

A2 - Wallace, Zach

A2 - Bhana, Suleman

A2 - Hausmann, Jon

A2 - Machado, Pedro

A2 - Liew, David

A2 - Marques, Claudia

A2 - LaCaille, Diane

A2 - Johnson, Sindhu

A2 - Devakandan, Keshini

A2 - Thorne, Carter

A2 - Li, Mengtao

A2 - Knitza, Johannes

A2 - Conway, Richard

A2 - Inita, Bulina

A2 - Tehozol, Erick Adrian Zamora

A2 - Almaghlouth, Ibrahim

A2 - Youngstein, Taryn

A2 - Machado, Pedro

A2 - Beesley, Richard

A2 - Hyrich, Kimme

A2 - Kilian, Adam

A2 - Danila, Maria

A2 - Amigues, Isabelle

A2 - Chock, Eugenia

A2 - Le-Wandowski, Laura

A2 - Hausmann, Jon

A2 - Konig, Maximilian

A2 - Wallace, Beth

A2 - Syed, Reema

A2 - Jayatilleke, Arundathi

A2 - Singh, Namrata

A2 - Patel, Aarat

A2 - Wysham, Katherine

A2 - Nolan, Marc

N1 - Funding Information: Disclosures: Dr. Kim reports personal fees from Exagen Diagnostics and GlaxoSmithKline and grants from the National Institutes of Health and the Rheumatology Research Foundation outside the submitted work. Dr. Sparks reports grants from the National Institute of Allergy and Infectious Diseases Autoimmune Centers of Excellence, National Institutes of Health, during the conduct of the study and personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum outside the submitted work. Dr. Berenbaum reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, No-vartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica, and 4P Pharma outside the submitted work. Dr. Korsten reports personal fees from GlaxoSmith-Kline, Sanofi-Aventis, Pfizer, AbbVie, Novartis Pharma, Lilly, and Bristol-Myers Squibb outside the submitted work. Dr. Sat-tui reports funding from a Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319). Dr. Ugarte-Gil reports grants from Pfizer and Janssen outside the submitted work. Dr. Grainger reports nonfinancial support from Pfizer Australia and Janssen Australia and personal fees from Pfizer Australia, Cornerstones, Janssen New Zealand, and Novartis outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www .acponline.org/authors/icmje/ConflictOfInterestForms.do?ms Num=M20-1223.

PY - 2020/6/16

Y1 - 2020/6/16

UR - http://www.scopus.com/inward/record.url?scp=85083710801&partnerID=8YFLogxK

UR - https://rheum-covid.org/about/

U2 - 10.7326/M20-1223

DO - 10.7326/M20-1223

M3 - Comment/debate

C2 - 32227189

AN - SCOPUS:85083710801

SN - 0003-4819

VL - 172

SP - 819

EP - 821

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 12

ER -

A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this